Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 35, 2017, Pages E7348-E7357

  Pallesen, Jesper ^a   Wang, Nianshuang ^b   Corbett, Kizzmekia S ^c   Wrapp, Daniel ^b   Kirchdoerfer, Robert N ^a   Turner, Hannah L ^a   Cottrell, Christopher A ^a   Becker, Michelle M ^d   Wang, Lingshu ^c   Shi, Wei ^c   Kong, Wing Pui ^c   Andres, Erica L ^d   Kettenbach, Arminja N ^b   Denison, Mark R ^d,e   Chappell, James D ^d   Graham, Barney S ^c   Ward, Andrew B ^a   McLellan, Jason S ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronavirus; Cryo EM; Neutralizing antibody; Peplomer; X ray crystallography

Indexed keywords

ANTIGEN; CORONAVIRUS SPIKE GLYCOPROTEIN; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G; PROTEIN BINDING; VIRUS ANTIBODY; VIRUS RECEPTOR; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGEN STRUCTURE; ARTICLE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; DRUG DESIGN; DRUG STRUCTURE; FEMALE; IMMUNOGENICITY; MEMBRANE FUSION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; ANIMAL; BAGG ALBINO MOUSE; CORONAVIRIDAE; CORONAVIRUS INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; PROCEDURES; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; VACCINATION; VIROLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRIDAE; CORONAVIRUS INFECTIONS; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINATION; VIRAL VACCINES;

EID: 85028522287     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1707304114     Document Type: Article

References (87)

1. Woo PC, Lau SK, Huang Y, Yuen KY (2009) Coronavirus diversity, phylogeny and in-terspecies jumping. Exp Biol Med (Maywood) 234:1117–1127.
2. Peiris JS, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319–1325.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367: 1814–1820.
4. van Boheemen S, et al. (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3:e00473–12.
5. Azhar EI, et al. (2014) Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 370:2499–2505.
6. Alraddadi BM, et al. (2016) Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22: 49–55.
7. Fehr AR, Channappanavar R, Perlman S (2017) Middle East respiratory syndrome: Emergence of a pathogenic human coronavirus. Annu Rev Med 68:387–399.
8. Mohd HA, Al-Tawfiq JA, Memish ZA (2016) Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir. Virol J 13:87.
9. Oboho IK, et al. (2015) 2014 MERS-CoV outbreak in Jeddah—A link to health care facilities. N Engl J Med 372:846–854.
10. Ki M (2015) 2015 MERS outbreak in Korea: Hospital-to-hospital transmission. Epidemiol Health 37:e2015033.
11. Gierer S, et al. (2013) The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87:5502–5511.
12. Li F (2016) Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 3:237–261.
13. Millet JK, Whittaker GR (2014) Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci USA 111:15214–15219.
14. Lu G, et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500:227–231.
15. Raj VS, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251–254.
16. Wang N, et al. (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:986–993.
17. Walls AC, et al. (2016) Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531:114–117.
18. Kirchdoerfer RN, et al. (2016) Pre-fusion structure of a human coronavirus spike protein. Nature 531:118–121.
19. Walls AC, et al. (2016) Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol, 10.1038/ nsmb.3293.
20. Gui M, et al. (2017) Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 27: 119–129.
21. Corti D, et al. (2015) Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA 112: 10473–10478.
22. Modjarrad K, et al. (2016) A roadmap for MERS-CoV research and product development: Report from a World Health Organization consultation. Nat Med 22:701–705.
23. Tang XC, et al. (2014) Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 111: E2018–E2026.
24. Jiang L, et al. (2014) Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 6:234ra259.
25. Li Y, et al. (2015) A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 25:1237–1249.
26. Zhang N, Tang J, Lu L, Jiang S, Du L (2015) Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res 202:151–159.
27. Sui J, et al. (2008) Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog 4:e1000197.
28. ter Meulen J, et al. (2006) Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med 3:e237.
29. Mitsuki YY, et al. (2008) A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV. Microbes Infect 10:908–915.
30. Qiu X, et al. (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53.
31. Wang L, et al. (2015) Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 6:7712.
32. Sanders RW, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8875–8889.
33. Impagliazzo A, et al. (2015) A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349:1301–1306.
34. Yassine HM, et al. (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21:1065–1070.
35. Ekiert DC, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324:246–251.
36. Krarup A, et al. (2015) A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143.
37. Kong L, et al. (2016) Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun 7:12040.
38. Shirato K, Kawase M, Matsuyama S (2013) Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 87:12552–12561.
39. Sjoberg M, Loving R, Lindqvist B, Garoff H (2017) Sequential activation of the three protomers in the Moloney murine leukemia virus Env. Proc Natl Acad Sci USA 114: 2723–2728.
40. Arabi YM, et al. (2017) Middle East respiratory syndrome. N Engl J Med 376:584–594.
41. Carr CM, Kim PS (1993) A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 73:823–832.
42. Qiao H, et al. (1998) Specific single or double proline substitutions in the “spring-loaded” coiled-coil region of the influenza hemagglutinin impair or abolish membrane fusion activity. J Cell Biol 141:1335–1347.
43. Pancera M, et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:455–461.
44. Lyumkis D, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484–1490.
45. Julien JP, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342:1477–1483.
46. McLellan JS, et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592–598.
47. Daniel C, et al. (1993) Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure. J Virol 67:1185–1194.
48. Zhang H, et al. (2004) Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 78:6938–6945.
49. Lee JH, Ozorowski G, Ward AB (2016) Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043–1048.
50. Kong R, et al. (2016) Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352:828–833.
51. Kwong PD, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678–682.
52. Munro JB, et al. (2014) Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346:759–763.
53. Dveksler GS, et al. (1991) Cloning of the mouse hepatitis virus (MHV) receptor: Expression in human and hamster cell lines confers susceptibility to MHV. J Virol 65: 6881–6891.
54. Peng G, et al. (2011) Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. Proc Natl Acad Sci USA 108:10696–10701.
55. Kubo H, Yamada YK, Taguchi F (1994) Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino-acids of the murine coronavirus spike protein. J Virol 68:5403–5410.
56. Matsuyama S, Taguchi F (2009) Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis. J Virol 83: 11133–11141.
57. Huang X, et al. (2015) Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol 89:7202–7213.
58. Graham BS (2016) Vaccines against respiratory syncytial virus: The time has finally come. Vaccine 34:3535–3541.
59. Suloway C, et al. (2005) Automated molecular microscopy: The new Leginon system. J Struct Biol 151:41–60.
60. Lander GC, et al. (2009) Appion: An integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol 166:95–102.
61. Voss NR, Yoshioka CK, Radermacher M, Potter CS, Carragher B (2009) DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy. J Struct Biol 166:205–213.
62. Ogura T, Iwasaki K, Sato C (2003) Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. J Struct Biol 143:185–200.
63. Li X, et al. (2013) Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat Methods 10:584–590.
64. Mindell JA, Grigorieff N (2003) Accurate determination of local defocus and specimen tilt in electron microscopy. J Struct Biol 142:334–347.
65. Scheres SH (2012) RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol 180:519–530.
66. Webb B, Sali A (2016) Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci 86:2 9 1–2 9 37.
67. Pettersen EF, et al. (2004) UCSF Chimera—A visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612.
68. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–2132.
69. DiMaio F, et al. (2015) Atomic-accuracy models from 4.5-A cryo-electron microscopy data with density-guided iterative local refinement. Nat Methods 12:361–365.
70. DiMaio F, Tyka MD, Baker ML, Chiu W, Baker D (2009) Refinement of protein structures into low-resolution density maps using rosetta. J Mol Biol 392:181–190.
71. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58:1948–1954.
72. Chen VB, et al. (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12–21.
73. Barad BA, et al. (2015) EMRinger: Side chain-directed model and map validation for 3D cryo-electron microscopy. Nat Methods 12:943–946.
74. Agirre J, et al. (2015) Privateer: Software for the conformational validation of carbohydrate structures. Nat Struct Mol Biol 22:833–834.
75. Lutteke T, Frank M, von der Lieth CW (2005) Carbohydrate Structure Suite (CSS): Analysis of carbohydrate 3D structures derived from the PDB. Nucleic Acids Res 33: D242–D246.
76. Majeed S, et al. (2003) Enhancing protein crystallization through precipitant synergy. Structure 11:1061–1070.
77. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG (2011) iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67:271–281.
78. Evans PR, Murshudov GN (2013) How good are my data and what is the resolution? Acta Crystallogr D Biol Crystallogr 69:1204–1214.
79. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40:658–674.
80. Jackson RN, McCoy AJ, Terwilliger TC, Read RJ, Wiedenheft B (2015) X-ray structure determination using low-resolution electron microscopy maps for molecular replacement. Nat Protoc 10:1275–1284.
81. DiMaio F, et al. (2011) Improved molecular replacement by density- and energy-guided protein structure optimization. Nature 473:540–543.
82. Cowtan K (2006) The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallogr D Biol Crystallogr 62:1002–1011.
83. Morin A, et al. (2013) Collaboration gets the most out of software. eLife 2:e01456.
84. Scobey T, et al. (2013) Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci USA 110:16157–16162.
85. Ashkenazy H, et al. (2016) ConSurf 2016: An improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res 44:W344–W350.
86. Peng G, et al. (2012) Crystal structure of bovine coronavirus spike protein lectin domain. J Biol Chem 287:41931–41938.
87. Rusin SF, Schlosser KA, Adamo ME, Kettenbach AN (2015) Quantitative phosphoproteomics reveals new roles for the protein phosphatase PP6 in mitotic cells. Sci Signal 8:rs12.